Skip to content

A study of humoral immune characteristics and real-world protective effects of influenza vaccination for medical staff in high-risk departments

A study of humoral immune characteristics and real-world protective effects of influenza vaccination for medical staff in high-risk departments

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078345
Enrollment
Unknown
Registered
2023-12-05
Start date
2023-09-22
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Interventions

Vaccination group (observation group):None
Unvaccinated group (control group):None

Sponsors

The Third People's Hospital of Shenzhen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Vaccination group (observation group): 50 medical staff from high-risk departments who received quadrivalent influenza vaccine were included. Inclusion criteria. 1) Staff of high-risk departments in the hospital; 2) Voluntary participation in this study; 3) Voluntary vaccination against influenza; 4) Signed informed consent; (5) No plans for further training, long-term vacation, etc. from the date of signing the consent form to six months. Unvaccinated group (control group): for medical staff of high-risk departments who did not receive quadrivalent influenza vaccine, 50 people were included. Inclusion criteria. 1) Staff of high-risk departments in the hospital; 2) Voluntary participation in this study; 3) Those with contraindications to the current vaccination with quadrivalent influenza virus lysate vaccine; 4) Signed informed consent; 5) No plans for further training or long-term vacation from the date of signing the consent form to six months.

Exclusion criteria

Exclusion criteria: The vaccination group (observation group): those with contraindications to the current vaccination with quadrivalent influenza virus lysate vaccine (1) Allergy to the vaccine components, any excipients, residues such as neomycin, formaldehyde or Triton X-100 in this vaccination; 2) Those who are suffering from moderate or severe fever or acute infection. The unvaccinated group (control group): 1) Have been recently vaccinated against influenza; 2) unwilling to participate in this study.

Design outcomes

Primary

MeasureTime frame
Indicators of humoral immunity;

Secondary

MeasureTime frame
Influenza-like cases;Influenza virus PCR;

Countries

China

Contacts

Public ContactHongzhou Lu

The Third People's Hospital of Shenzhen

luhongzhou@szsy.sustech.edu.cn+86 189 3081 0088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026